Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
NanoVelcro CTC Assays for Detection and Characterization of Circulating Tumor Cells – Towards Non-Invasive Cancer Diagnostics Tseng, Hsian-Rong Professor Tseng’s research team is on a mission to make dramatic improvements in cancer patient quality of life through its patented high sensitivity liquid biopsy nanotechnology for cancer detection and monitoring. In a partnership with UCLA Health Systems and Cedars-Sinai Medical Center (CSMC), the team has been developing its proprietary NanoVelcro CTC Assays for highly sensitive enumeration and molecular characterization of CTCs in prostate cancer, hepatocellular carcinoma, pancreatic cancer, and other solid tumors. Through a long-standing collaboration with the Urologic Oncology Program of the Samuel Oschin Comprehensive Cancer Institute at CSMC, the collaborative team identified a subpopulation of CTCs morphologically defined by distinctly smaller nuclei, named very-small-nuclear CTCs (vsnCTCs). The presence of vsnCTCs is strongly associated with the visceral metastasis in prostate cancer, a clinical event tied to aggressive biology and extremely short survival. With the UCLA Surgery Program, the joint team has been exploring the use of CTC enumeration for diagnosis and staging of hepatocellular carcinoma and pancreatic cancer, and evaluating its promise to guide the selection of patients for curative liver transplantation and pancreatectomy, respectively. CytoLumina Technologies Corp. is a biotechnology company spun-out from Professor Tseng’s lab at UCLA Medical School. CytoLumina is honored to contribute to the White House Cancer Moonshot program, in pursuit of accelerating blood profiling diagnostic technologies for the benefit of patient quality of life. Under Professor Tseng’s leadership, CytoLumina has been seeking for research and clinical partners world-wide in order to further broaden the impact of NanoVelcro CTC Assays.